Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial
National Institute of Allergy and Infectious Diseases of the National Institutes of Health. Amubarvimab and romlusevimab supplied by Brii Biosciences.
Authors
- David M. Margolis (ORCID: https://orcid.org/0000-0001-5714-0002)
- Kara W Chew (ORCID: https://orcid.org/0000-0003-4865-4348)
- Nikolaus Jilg (ORCID: https://orcid.org/0000-0001-9154-2769)
- Joseph J. Eron (ORCID: https://orcid.org/0000-0002-4938-0644)
- Carlee Moser (ORCID: https://orcid.org/0000-0001-5601-9112)
- Arzhang Cyrus Javan
- Jonathan Z. Li (ORCID: https://orcid.org/0000-0001-9914-9662)
- Davey M. Smith (ORCID: https://orcid.org/0000-0003-3603-1733)
- David A. Wohl (ORCID: https://orcid.org/0000-0002-7764-0212)
- Teresa H. Evering
- Eric S. Daar (ORCID: https://orcid.org/0000-0003-1880-7331)
- Judith S. Currier (ORCID: https://orcid.org/0000-0003-4279-4737)
- Justin Ritz (ORCID: https://orcid.org/0000-0001-6307-4849)
- Michael D. Hughes (ORCID: https://orcid.org/0000-0001-8562-2316)
Institutions
- University of North Carolina at Chapel Hill (US)
- Brigham and Women's Hospital (US)
- National Institutes of Health (US)
- Harvard University (US)
- University of California, Los Angeles (US)
- Cornell University (US)
- UCLA Medical Center (US)
- University of California San Diego (US)
- Massachusetts General Hospital (US)
- Harbor–UCLA Medical Center (US)
- Weill Cornell Medicine (US)
Publication Details
- Journal
- EClinicalMedicine
- Published
- 2024-08-16
- DOI
- https://doi.org/10.1016/j.eclinm.2024.102787
- Citations
- 3
- Primary Topic
- Long-Term Effects of COVID-19
- Type
- article
- Field-Weighted Citation Impact
- 1.11
Funders
- ACT Government
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases